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ANSWERS
1. Diagnosis: severe panniculitis due to Bartonella
henselae infection.
In this patient, a negative serology work-up
included HIV-I and HIV-II, Borrelia burgdorferi,
Ehrlichia chaffeensis, Histoplasma capsulatum, Blasto-
myces dermatitidis, Coccidioides immitis, Chlamydia
trachomatis, Coxiella burnetii, Brucella spp., Yersinia
enterocolitica, and antibodies against native DNA.
Bartonella henselae serum IgG titers were markedly
elevated (>1024; IgM< 20, by IFA), althoughDNA
ampliﬁcation (PCR) of a biopsy sample failed to
establish the diagnosis. Detectable serum IgG (256;
IgM< 20) for Bartonella quintanawas considered to
be due to intragenus antigen cross-reaction. Treat-
ment with intravenous azithromycin (500mg
daily) was initiated and continued for two weeks.
A rapid clinical response was observed, and
within 96 h the right arm lesion started to resolve.
Constitutional symptoms were slower to abate,
and subsided in 10–14 days. Despite the inability
to directly identify B. henselae in the lesion, the
exposure history, strong as well as serologic evi-
dence and clinical response to antibioticsmake this
case likely to be an unusual cutaneous manifesta-
tion associated with B. henselae infection.
2. Since the original description of oculoglandular
syndrome in 1889, the spectrum of disease asso-
ciated with Bartonella (Rochalimaea) henselae infec-
tion has expanded considerably [1,2]. In the
immunocompetent individual, cat scratch disease
(CSD) is often localized and self-limiting, and
frequently resolves spontaneously over a period
of months [3,4]. Systemic dissemination is uncom-
mon, and may present as bacillary angiomatosis,
peliosis hepatis, bacteremiawith endocarditis, hep-
atosplenic abscesses, generalized lymphadenitis,
and aseptic meningitis [5]. Bartonella neuroretini-
tis has recently been recognized as an infectious
cause of potentially reversible bilateral retinitis in
immunocompetent individuals [6]. However, sep-
tal panniculitis, with the exception of a case of
erythema nodosum, has not been described in this
setting.
3. Our understanding of infections due to Barto-
nella henselae, an arthropod-borne proteobacterium
that prefers the intracellular lifestyle and is asso-
ciated with a variety of clinical syndromes, is
evolving [1–8]. The presence of a papule at the
primary inoculation site is the most frequent der-
matologic manifestation of CSD, and may be pre-
sent in 60–90% of patients [5]. Other uncommon
cutaneous lesions include generalizedmaculopap-
ular, or urticarial, eruptions, erythema nodosum,
erythema marginatum, leukocytoclastic vasculitis,
erythema annulare, and multiple granulomatous
lesions [5,7,8]. A Sweet’s syndrome-like skin erup-
tion with arthralgia and lymphadenopathy has
been described in a healthy woman that respon-
ded favorably to treatment with oral prednisone
[8]. In the case presented, a complete lack of peri-
vascular lymphocytic/granulocytic inﬁltration
and accompanying extensive necrosis of subcuta-
neous fat (Figure 1) was inconsistent with the diag-
nosis of Sweet’s syndrome or erythema nodosum.
4. Ten weeks after the initial response to azithro-
mycin, the patient presented with identical symp-
toms. An erythematous, tender nodule on the
anterior–medial aspect of the right mid-thigh
(Figure 2) was accompanied by profound pros-
tration. Treatment with intravenous azithromycin
(500mg daily) was associated with rapid resolu-
tion of the right leg lesion (<7days), while con-
stitutional symptoms resolved gradually over two
to threeweeks. A4-fold decline in speciﬁc immu-
noglobulin (IgG 512) titers from >1024 was obser-
ved at the end of this three-week therapy. The
patient presentedwith a third relapse,marked by a
deep right gluteal painful subcutaneous swelling,
four weeks after the antibiotic was discontinued. A
favorable response to intravenous azithromycin
(500mg daily) occurred rapidly, and his energy
level returned to normal in the following weeks.
Intravenous antimicrobial therapy was continued
for fourweeks,andoralazithromycin(600mgdaily)
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was given for another eight weeks. Twelve weeks
after the discontinuation of treatment, B. henselae
titers had become non-detectable (IgG< 64), and
no further relapses were noticed at 24-month fol-
low-up.
A favorable response to azithromycin in this
patient was consistent with the accelerated de-
crease in the size of affected lymph nodes among
children with CSD who were treated with azi-
thromycin compared with other antimicrobials,
despite favorable in vitro susceptibility proﬁles
[3,9,10]. In our patient, recurring, painful septal
panniculitis appears to be an immunologically
triggered process that was probably related to a
recently acquired B. henselae infection, and
response to prolonged azithromicin therapy was
excellent.
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Figure 1 Extensive fat necrosis and
septal panniculitis is observed
(H&E, magnification 100). There
is no evidence of inflammatory
infiltrates including histiocytes
around small intralobular venules
(arrow) or arteriole (arrow head).
Figure 2 An identical tender, firm,
non-fluctuant, nodular lesion along
the anterior–medial aspect of the
right mid-thigh that developed
10weeks after the initial episode of
septal panniculitis involving the
right upper arm.
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